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Background: The objective of this study was to identify breast cancer patients with a high risk of developing brain
metastases who may benefit from pre-emptive medical intervention.
Methods: Medical records of 352 breast cancer patients with local or locoregional disease at diagnosis were
retrospectively analysed. The brain metastasis-free survival was estimated using the Kaplan-Meier method and
patient groups were compared using the log rank test. The simultaneous relationship of multiple prognostic factors
was assessed using Cox’s proportional hazard regression analysis. The Fisher exact test was used to test the difference
of proportions for statistical significance.
Results: On univariate analysis, statistically highly significant unfavourable risk factors for the brain metastasis-free
survival were negative ER status, negative PR status, and triple negative tumor subtype. Young age at diagnosis
(≤35 years) and advanced disease stage were not statistically significant (p = 0.10). On multivariate analysis, the only
independent significant factor was the ER status (negative ER status; hazard radio (95% confidence interval), 5.1
(1.8-14.6); p = 0.003). In the subgroup of 168 patients with a minimum follow-up of 24 months, 49 patients
developed extracranial metastases as first metastatic event. Of those, 7 of 15 (46.6%) with a negative ER status
developed brain metastases compared to 5 of 34 (14.7%) with a positive ER status (Fisher exact test, p = 0.03). The
median time interval (minimum-maximum) between the diagnosis of extracranial and brain metastases was
7.5 months (1-30 months).
Conclusions: Breast cancer patients with extracranial metastasis and negative ER status exhibited an almost 50%
risk of developing brain metastasis during their course of disease. Future studies are highly desired to evaluate the
efficacy of pre-emptive medical intervention such as prophylactic treatment or diagnostic screening for high risk
breast cancer patients.
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The incidence of brain metastases in breast cancer is
about 5% [1,2]. While patients with early breast cancer
rarely develop brain metastases, symptomatic brain
metastases are diagnosed in 10% to 16% of patients with
metastatic breast cancer [1,3,4]. Advances in systemic treat-
ment have substantially improved the overall survival of* Correspondence: vrudat@saadmedical.com
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reproduction in any medium, provided the oradvanced breast cancer patients [5,6], and brain metas-
tases are emerging as an important sanctuary site. An
increasing proportion of patients have been observed
suffering from symptomatic brain metastases often at a
time when their extracranial disease is apparently under
control [5,7]. The survival of patients with symptomatic
multiple brain metastases is poor even after palliative
whole brain irradiation [8,9], and better in patients with
brain oligometastases where surgical resection or stereo-
tactic radiotherapy can be applied [10-13].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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risk of developing brain metastases would enable pre-
emptive intervention such as prophylactic treatment or
diagnostic screening with the potential to improve the
outcome.
Reported risk factors for brain metastases in breast
cancer patients include young age at first diagnosis,
presence of lung metastases, short disease-free survival,
ER negative tumors, triple-negative tumor subtype, HER2
overexpression and BRCA1 phenotype [1,5,14-19].
The objective of this study was to identify a subgroup
of breast cancer patients with a high risk of developing
brain metastases who may benefit from pre-emptive
medical intervention.
Methods
Medical records were retrospectively reviewed of female
breast cancer patients who consulted Saad Specialist
Hospital between 2006 and 2013. Eligibility criteria for
the analysis were histologically confirmed diagnosis of
invasive breast cancer. Patients with distant metastases,
synchronous, or metachronous cancer at diagnosis were
excluded from the analysis. Staging procedures included
complete history and physical examination, laboratory
assessments, and diagnostic bilateral mammogram. Where
indicated, ultrasonography of the breast and abdomen,
chest radiograph, and radionuclide bone scan were per-
formed. Selected patients received magnetic resonance
imaging (MRI) of the breast, computerized tomography
(CT), or positron emission tomography computed tom-
ography (PET-CT). Patients were presented and dis-
cussed in an interdisciplinary Tumor Board Meeting,
and a treatment recommendation was generated in
accordance with the guidelines of the National Compre-
hensive Cancer Network (NCCN). Breast conserving
surgery (BCS) consisted of wide local excision or lumpec-
tomy and axillary dissection or sentinel lymph node biopsy
in selected patients. After modified radical mastectomy, in
selected patients breast reconstruction with TRAM-flap
was performed. Surgery was followed by chemotherapy
and hormonal therapy where indicated. Dependent on the
T status, N status, hormone receptor status, age (≤35 years
versus >35 years), and menopausal status, four cycles
of Adriamycin/Cyclophosphamide (AC) or six cycles
of Cyclophosphamide/Methotrexate/5-FU (CMF) were
prescribed for node negative patients, and four cycles of
AC followed by four cycles of paclitaxel or, alternatively,
three cycles of 5-FU/epirubicin/cyclophosphamide (FEC)
followed by three cycles of docetaxel for node positive pa-
tients. Endocrine therapy using tamoxifen or aromatase
inhibitors was prescribed where indicated. Trastuzumab
was added according to the HER2 status and prescribed
for at least one year. Triple negative tumor subtype pa-
tients were usually treated with four cycles of AC followedby four cycles of paclitaxel. In selected patients neoadju-
vant chemotherapy was applied. Postoperative radio-
therapy was performed in all patients after BCS. A total
dose of 50.4 Gy in 28 fractions was prescribed, followed
by a boost of 10 Gy in 5 fractions in all patients younger
than 50 years. Postmastectomy radiotherapy of the chest
wall was given in patients with at least one positive loco-
regional lymph node. The prescribed dose was 50 Gy in
25 fractions. Usually opposed tangential beam techniques
using three-dimensionally planned conformal radiotherapy
(3DCRT) or intensity modulated radiotherapy (IMRT)
were applied for the treatment of the whole breast or the
chest wall [20]. Follow-up examinations were scheduled
every three months in the first year, then every six months
for 4 years. PET-CT was performed in many patients
during the follow-up. Symptomatic brain metastases were
diagnosed by imaging (usually MRI). Breast cancer was
classified according to the International Union Against
Cancer (UICC), with group clinical and pathological
staging according to the American Joint Committee on
Cancer (AJCC, 6th edition). Data were entered into a
computerized database (MS Access 2010) and analysed
using a statistical software package (Statistica 12). This
study was approved by the local Institutional Review Board
“Institutional Review Board - Saad Specialist Hospital
(Registration number: H-05-KH-001, King Abdul-Aziz
City of Science and Technology – KACST)” and per-
formed in compliance with the Helsinki Declaration.
Immunohistochemistry
Sections with a thickness of four μm were cut from par-
affin blocks and used for immunohistochemical staining
using the iVIEW DAB detection kit on BenchMark auto-
stainer (Ventana, Tucson, AZ, USA). The clones of anti-
bodies SP1, 1E2, and 4B5 were used to evaluate the ER-a,
PR, and HER2 status. The Allred scoring system was used
to assess the ER and PR status [21]. In summary, a total
Allred score was obtained by the summation of proportion
score (PS) and intensity score (IS). PS is assigned depend-
ing on the proportion of positive cells (0 = none; 1 < 1%;
2 = 1% - < 1/10; 3 = 1/10 - < 1/3; 4 = 1/3 - < 2/3; 5 = 2/3), IS
(0 = none; 1 = weak; 2 = intermediate; 3 = strong). A total
score of 3 or more was considered as positive; scores 0
and 1 and 2 were considered negative. The American
Society of Clinical Oncology/College of American Pathol-
ogists (ASCO/CAP) guideline recommendations were
used to evaluate the HER2 status [22]. Briefly, score 0
indicates no staining in invasive tumor cells. Score + 1
indicates weak incomplete membrane staining in any
proportion of invasive tumor cells or weak complete
membrane staining in <10% of cells. Score + 2 indicates
complete membrane staining in nonuniform or weak
but with obvious circumferential distribution in = 10% of
cells, or intense complete membrane staining in = 30% of
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staining of >30% of invasive tumor cells. Scores 0 and + 1
were considered negative; + 2 equivocal; and + 3 positive.
Gene expression profiling studies have shown that im-
munohistochemistry of paraffin sections is a reliable
surrogate for molecular classification of invasive breast
cancers [23-28]. Based on this finding, patients of this
study were categorized as follows: luminal A (ER+, PR+,
HER2-), luminal B (ER + and/or PR+, HER2+), HER2
overexpressing (ER-, PR-, HER2+), and triple negative
(ER-, PR-, HER2-).
Statistical analysis
The brain metastasis-free survival was estimated using
the Kaplan-Meier method, and patient groups were
compared using the log rank test. The brain metastasis-
free survival was defined as the time between diagnosis
of breast cancer and the detection of brain metastases.
Patients who have not developed brain metastases were
censored at the time of their last follow-up. The simul-
taneous relationship of multiple prognostic factors on
the brain metastasis-free survival was assessed using
Cox’s proportional hazard regression analysis. The re-
gression coefficients were estimated by the maximum
likelihood method, and model selection was performed
by a stepwise strategy using the likelihood ratio test. The
Fisher exact test and the Mann-Whitney U test were
used to test the difference between patient groups for
statistical significance. A 5% significance level was used
and all tests are two-sided.
Results
Three hundred and fifty-two patients were analyzed in
this study. The median follow-up time of the censored
patients was 19.5 months (3-72 months). Eight patients
died during the follow-up. The treatment of the patients
consisted of mastectomy in 203 patients (57.7%), breast
conserving surgery in 139 patients (39.5%), and non-
surgical treatment in 10 patients (2.8%). As expected,
compared to what is generally reported in the United
States and Europe the patients of this study were diag-
nosed at a strikingly younger age and more advanced
stage of the disease (Table 1) [29]. The median age
(minimum-maximum) at diagnosis was 48 years (22-94
years) and the median body mass index (minimum-max-
imum) 29.9 (17.7-66.4) [30].
On univariate analysis, the ER status (Figure 1), the PR
status, and the tumor subtype (Figure 2) had a statistically
highly significant impact on the brain metastasis-free
survival (Table 1). A closer look at the tumor subtype
revealed that the triple negative receptor status had a
significantly adverse impact on the brain metastasis-
free survival (log rank test, p < 0.01) compared to the
combined subtypes luminal A, luminal B and HER2overexpressing. Young age at diagnosis (≤35 years) and
disease stage showed no statistically significant impact
(p = 0.10). On multivariate analysis, the only independent
significant factor on the brain metastasis-free survival was
the ER status (negative ER status, hazard radio (95% confi-
dence interval), 5.1 (1.8-14.6); p = 0.003). Of 109 patients
with a negative ER status 11 developed brain metastasis
during the follow-up period and of 238 ER positive pa-
tients five.
In the subgroup of patients with a minimum follow-up
time of 24 months of the censored patients, 16 of 168
patients (9.5%) developed brain metastasis. Of 49 pa-
tients with extracranial metastases at first metastatic
event 12 (24.4%) later developed brain metastases. The
median time interval (minimum-maximum) between the
diagnosis of extracranial and brain metastases was
7.5 months (1-30 months). In one patient brain metasta-
ses and extracranial metastases were detected at the
same time, and three patients developed brain metasta-
ses as the first or only distant metastasis. Of 15 patients
with extracranial metastases and a negative ER status
seven (46.6%) developed brain metastases and of 34
patients with a positive ER status five (14.7%). The dif-
ference between the above proportions is statistically
significant (Fisher exact test, p = 0.03). The median
time interval between the diagnosis of extracranial and
brain metastasis of ER negative patients was 5 months
(1-11 months) and 18 months (3-30 months) for ER
positive patients (Mann-Whitney U test; p = 0.07).
Discussion
In our retrospective study breast cancer patients with
extracranial metastasis and negative ER status exhibited a
46.6% risk of developing brain metastasis during the
course of their disease. For this patient group pre-emptive
medical intervention such as prophylactic treatment or
diagnostic screening may be of benefit.
The most promising pre-emptive medical intervention
to improve the outcome may be prophylactic cranial
irradiation. Autopsy studies have shown a high frequency
of occult brain metastasis in patients with metastatic
breast cancer [3,31]. Once brain metastases are diagnosed
the survival is usually poor. Reported median survival
rates of breast cancer patients with brain metastasis are
usually in the range of 3 to 8 months [9,14,16,17,32].
Prophylactic cranial irradiation has been shown to ef-
fectively reduce the frequency of brain metastases and
to improve the survival in lung cancer [33-35]. In a
study of extensive small cell lung cancer, prophylactic
cranial irradiation reduced the frequency of brain metas-
tasis from 40.4% to 14.6% (p <0.001) and improved the
survival rate from 13.3% to 27.1% one year after
randomization [36]. The total radiation dose required
for effective prophylactic whole brain irradiation is
Table 1 Univariate analysis (Kaplan-Meier method) of possible factors associated with the development of brain
metastasis of non-metastatic breast cancer patients at diagnosis
Characteristics n % 3-year brain metastasis-free survival -95% CI +95% CI p-value*
Age (years) 0.10
≤35 36 10.3 0.87 0.74 1.00
>35 316 89.7 0.95 0.92 0.99
Menopausal status 0.33
Pre-menopausal 165 47.0 0.95 0.91 0.99
Post-menopausal 187 53.0 0.94 0.88 0.99
Body Mass Index 0.88
<25 60 17.1 0.95 0.88 1.00
25-29 118 33.6 0.96 0.91 1.00
≥30 174 49.3 0.93 0.88 0.99
T stage 0.19
0-2 200 56.7 0.96 0.92 1.00
3-4 152 43.3 0.93 0.87 0.99
N stage 0.19
0-1 253 72.1 0.95 0.91 0.99
2-3 99 27.9 0.93 0.88 0.99
Stage 0.10
Localized 133 37.9 0.95 0.89 1.00
Regional 219 62.1 0.94 0.90 0.98
ER status <0.001
Positive 243 69.2 0.99 0.98 1.00
Negative 109 30.8 0.84 0.74 0.94
PR status 0.01
Positive 216 61.5 0.99 0.96 1.00
Negative 136 38.5 0.88 0.80 0.95
HER2 status 0.31
Positive 88 25.1 0.98 0.95 1.00
Negative 264 74.9 0.93 0.89 0.98
Tumor subtype <0.001
Triple negative 63 17.7 0.78 0.64 0.93
Her2 overexpressing 35 10.0 0.96 0.88 1.00
Luminal A 201 57.3 0.98 0.95 1.00
Luminal B 53 15.1 1.00 1.00 1.00
Abbreviation: 95% CI= 95% confidence interval of the 3-year brain metastasis-free survival; * = log rank test.
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radiation of symptomatic brain metastases [37], and
the corresponding toxicity is acceptable. Compared to
no prophylactic cranial irradiation, prophylactic cranial
irradiation showed a negative impact on verbal mem-
ory but no or only minimal impact on global cognitive
function or global health status [34,35,38]. Due to lack
of supporting data prophylactic cranial irradiation has
currently no role in breast cancer treatment [32]. The time
to the development of brain metastases varies between thepatients and it cannot be excluded that in selected patients
the seeding of tumors cells in the brain may occur after
a prophylactic whole brain irradiation. Future random-
ized trials are highly desired to evaluate the efficacy of
prophylactic cranial irradiation in high risk breast can-
cer patients.
Another promising prophylactic treatment for patients
with HER2 positive disease may be lapatinib, a dual
tyrosine-kinase inhibitor of EGFR and HER2. Fewer
cases with brain involvement at first progression were



































Figure 1 Brain metastases-free survival of breast cancer
patients with ER negative versus ER positive tumors.
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analysis of a randomized breast cancer study (4 versus 13,
total number of patients 399; p = 0.045) [39]. Lapatinib
plus capecitabine has also shown activity as first-line treat-
ment of brain metastases from HER2-positive breast can-
cer in a phase II study [40].
The value of diagnostic screening for brain metastases
of breast cancer patients is unclear. Patients with single





































Figure 2 Brain metastases-free survival of breast cancer
patients with triple negative versus luminal A, B and HER2
overexpressing.those with multiple metastases [41], and with surgery and
stereotactic radiotherapy effective treatment options are
available for patients with brain oligometastases. However,
early detection of brain metastases has not yet been shown
to improve survival [42,43].
The biology underlying the development of brain me-
tastases from breast cancer is only partially understood.
The hormone receptor status appears to be associated
with the development of brain metastasis as well as with
the control of extracranial disease. In addition, it has
been shown that the hormonal receptor status is associ-
ated with the risk of recurrence of brain metastases after
radiosurgery [44]. However, there is a body of evidence
suggesting that interactions of metastatic tumour cells
with the blood brain barrier and brain microenviron-
ment are also involved in the colonization process [45].
In our study, unfavourable prognostic factors for the
brain metastasis-free survival on univariate analysis in-
cluded negative ER status, negative PR status, triple nega-
tive tumor subtype, young age at diagnosis of breast
cancer and advanced stage of disease. No high risk group
could be defined using these factors for non-metastatic
women at diagnosis that would clinically justify pre-
emptive medical intervention.
Our results are in good agreement with other reports
from the literature. Evans et al. retrospectively analysed
219 breast cancer patients who had died with metastatic
disease [17]. The development of brain metastases was
significantly related to young age and to a negative ER sta-
tus. By combining age and ER status (age under 50 years
and negative ER status) the authors were able to identify
a group of women with a 53% risk of developing brain
metastasis. The brain metastases commonly occurred
after a good response of liver or lung metastases to
chemotherapy, and were often the only site of disease
progression. The median time between extracranial
metastatic presentation and the development of brain
metastases was also very similar in the compared stud-
ies (6-9 months; our study, 7.5 months).
Berghoff et al. analysed 213 breast cancer patients with
brain metastases [14]. The time interval between the
diagnosis of extracranial metastases until diagnosis of
brain metastases was significantly different between
breast cancer subtypes. Triple negative tumors showed
the shortest median time interval (14 months) followed
by HER2 positive (18 months) and luminal tumors
(34 months). A subgroup analysis showed that patients
with a positive ER/HER2 status had a significantly longer
time interval compared to ER negative/HER2 positive
disease (26 versus 15 months). The authors concluded
that patients with triple negative as well as patients with
ER negative/HER2 positive disease are at highest risk for
developing brain metastases early during their course of
disease.
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receptor status has been identified as significant un-
favourable factor for the probability of developing brain
metastases in a study of 215 metastatic breast cancer
patients [18].
Limitations of our study are related to the retrospective
study design and moderate patient numbers. The observed
lack of a statistically significant impact of a young age
at diagnosis and advanced disease stage on the brain
metastasis-free survival (p = 0.10) may be explained by
a possible insufficient statistical power of our study. A
selection bias cannot be fully excluded and results
should be confirmed by future prospective studies.
Conclusions
In conclusion, breast cancer patients with extracranial
metastasis and negative ER status exhibited an almost
50% risk of developing brain metastasis during their
course of disease. Future studies are highly desired to
evaluate the efficacy of pre-emptive medical intervention
such as prophylactic treatment or diagnostic screening
for high risk breast cancer patients.
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